Clinical pharmacy最新文献

{"title":"The study of the chemical composition of extracts from Sorbus aucuparia L. leaves and their influence on glucose metabolism and the excretory renal function in rats","authors":"О. В. Товчига, О. М. Маркін, С. Ю. Штриголь, О. В. Криворучко, O. Tovchiga, O. M. Markin, S. Shtrygol’, O. Kryvoruchko, А. Н. Маркин, С. Ю. Штрыголь, Е. В. Криворучко","doi":"10.24959/cphj.20.1514","DOIUrl":"https://doi.org/10.24959/cphj.20.1514","url":null,"abstract":"","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"43 1","pages":"26-34"},"PeriodicalIF":0.0,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90205883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and pharmaceutical features of using phytoneering medicines in the nefrological profile patients","authors":"I. Otrishko, S. Shebeko, N. Bezugla","doi":"10.24959/cphj.20.1521","DOIUrl":"https://doi.org/10.24959/cphj.20.1521","url":null,"abstract":"","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"48 1","pages":"36-45"},"PeriodicalIF":0.0,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75585686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the biochemical method of determining the ammonia level in the biological liquid samples as a tool for providing the quality of hyperamonemia diagnostics","authors":"С. В. Місюрьова, Н. О. Свід, В. Є. Доброва, І. А. Отрішко, В. В. Пропіснова, S. V. Misiurova, N. O. Svid, V. Y. Dobrova, I. Otrishko, V. V. Propisnova, С. В. Мисюрева, Н. А. Свид, В. Є. Доброва, И. А. Отришко, В. В. Прописнова","doi":"10.24959/cphj.20.1518","DOIUrl":"https://doi.org/10.24959/cphj.20.1518","url":null,"abstract":"Materials and methods. The object of the study was a standardized method for determining the level of ammonia. An “Ammonia NH 3 ” reagent manufactured by Randox, USA, and the known concentration of “Ammonia ethanol control – level 2” manufactured by Randox, USA as a control serum were selected for the study. The measurements were carried out on an Express Plus automatic biochemical analyzer manufactured by Bayer Corporation, Germany. When process ing the research results the descriptive statistics indicators were used, and a number of statistical evaluations were carried out. Results. The validation procedure consists of several stages. At the premises of the Laboratory of Clinical Diagnostics of the CDC of the NUPh the protocol and the validation report were developed to assess the suitability of the method for determining the concentration of ammonia in biological liquids by the enzymatic UV method on an Express Plus auto matic biochemical analyzer. Validation was carried out using reagents and control material manufactured by Randox, USA. The following validation characteristics of the method were determined: specificity, convergence and reproduc -ibility, correctness, measurement uncertainty. The assessment of the intermediate convergence and reproducibility of the ammonia determination method when working on the analyzer by two laboratory assistants of the same qualifica tion indicates the absence of gross errors in the operation of the device and statistically important differences during measurements. The assessment of the method correctness using the control material has proven that the systematic error is not significant (according to the given criterion of acceptability). Thus, this method provides the accuracy of measurements within the laboratory. The calculation of the expanded uncertainty has shown that the obtained values of the ammonia level can be considered accurate and reliable. Conclusions. The validation of the method for determining ammonia in the human blood by the enzymatic method has proven that this method has performance characteristics that meet the regulated ones, satisfies the established criteria, and the parameters measured correspond to the appropriate ones.","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85669356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The experimental study of the effect of suppositories “Melanizol” and “Klimedeks” on blood biochemical parameters in nonspecific vaginitis","authors":"О. В. Должикова, Л. М. Малоштан, М. О. Остапець, O. Dolzhykova, L. Maloshtan, M. O. Ostapets, Е. В. Должикова, Л. Н. Малоштан, М. А. Остапец","doi":"10.24959/cphj.20.1515","DOIUrl":"https://doi.org/10.24959/cphj.20.1515","url":null,"abstract":"","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"29 1","pages":"20-25"},"PeriodicalIF":0.0,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85935955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The analysis of the current state of quality management tools implementation in clinical trials of drugs in Ukraine","authors":"T. Kolodyezna, O. S. Popov, V. Dobrova","doi":"10.24959/cphj.20.1517","DOIUrl":"https://doi.org/10.24959/cphj.20.1517","url":null,"abstract":"","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76764663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diclofenac sodium.","authors":"Ralph E. Small","doi":"10.18578/bnf.253177925","DOIUrl":"https://doi.org/10.18578/bnf.253177925","url":null,"abstract":"The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of diclofenac sodium are reviewed. Diclofenac, the first nonsteroidal anti-inflammatory agent (NSAID) to be approved that is a phenylacetic acid derivative, competes with arachidonic acid for binding to cyclo-oxygenase, resulting in decreased formation of prostaglandins. The drug has both analgesic and antipyretic activities. Diclofenac is efficiently absorbed from the gastrointestinal tract; peak plasma concentrations occur 1.5 to 2.0 hours after ingestion in fasting subjects. Even though diclofenac has a relatively short elimination half-life in plasma (1.5 hours), it persists in synovial fluid. The drug is metabolized in the liver and is eliminated by urinary and biliary excretion. In clinical trials, diclofenac was as effective as aspirin, diflunisal, indomethacin, sulindac, ibuprofen, ketoprofen, and naproxen in improving function and reducing pain in patients with rheumatoid arthritis. For treatment of osteoarthritis, diclofenac was equivalent in efficacy to aspirin, diflunisal, indomethacin, sulindac, ibuprofen, ketoprofen, naproxen, flurbiprofen, mefenamic acid, and piroxicam. Diclofenac was as effective as indomethacin or sulindac in treating ankylosing spondylitis. The most frequent adverse effects reported for diclofenac were gastrointestinal, but these effects were fewer and less serious than occurred with aspirin or indomethacin; in addition, diclofenac caused fewer central nervous system reactions than indomethacin. Diclofenac is administered in divided doses with meals. The recommended total daily dosage is 100 to 150 mg (osteoarthritis and ankylosing spondylitis) or 150 to 200 mg (rheumatoid arthritis). Diclofenac is effective, but no more so than other NSAIDs. It is structurally distinct and offers another choice in the treatment of rheumatological conditions.","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"37 1","pages":"545-58"},"PeriodicalIF":0.0,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85342937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The study of the efficacy of combined medicines of quercetin and glucosamine derivatives in rats with the end-stage renal failure","authors":"S. Shebeko","doi":"10.24959/cphj.19.1512","DOIUrl":"https://doi.org/10.24959/cphj.19.1512","url":null,"abstract":"Chronic kidney disease (CKD) is the most significant pathology among diseases of the urinary system, which leads to the inevitable development of renal failure. Currently, there are no effective treatments for the end-stage form of CKD in clinical practice. Aim. To study of the effect of combined medicines of quercetin with glucosamine derivatives in the experiment using various routes of administration on the course of the end-stage renal failure. Materials and methods. The study was performed on the model of adenine-induced nephropathy in rats. Test samples were administered intragastrically (80 mg/kg) and intramuscularly (30 mg/kg) for 4 weeks starting in 4 weeks after beginning of the experiment. Corvitin was used as a reference drug in the dose of 34 mg/kg. The efficacy of test drugs was assessed by indicators of the kidney functional state and nitrogen metabolism. Results. In 8 weeks after the pathology simulation under the influence of both test objects a positive effect on the course of renal failure was observed. In this case, an injection combination of quercetin with N-acetylglucosamine significantly (p<0.05) exceeded the efficacy of the oral combination. Under its influence, there was an increase in glomerular filtration and urinary excretion of creatinine and urea. It indicates the normalization of the kidney functional state and nitrogen metabolism. Moreover, this combination was significantly (p<0.05) superior to the Corvitin effect by the efficacy level. Conclusions. In conditions of the end-stage renal failure in rats the injection combination of quercetin with N-acetylglucosamine was highly effective. It allows considering this combination to be a promising medicine for treating CKD at the IV-V stages.","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"77 1","pages":"17-23"},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87305000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The pharmacoeconomic analysis of the cost efficiency of trastuzumab in the adjuvant therapy of HER2 + early breast cancer","authors":"N. Bezdetko, O. Muzhychuk","doi":"10.24959/cphj.19.1507","DOIUrl":"https://doi.org/10.24959/cphj.19.1507","url":null,"abstract":"Breast cancer (BC) is the first among all oncological diseases in women and is one of the main causes of female mortality worldwide, including in Ukraine. The HER2 + subtype of breast cancer is characterized by the most unfavorable prognosis. The targeted drug trastuzumab significantly improves the 10-year survival rate of patients with HER2 + breast cancer, but at the same time significantly increases the cost of treatment. Aim. To assess pharmacoeconomically the adjuvant therapy of the early stage of HER2 + breast cancer with trastuzumab (Herceptin® medicine) from the perspective of the Ukrainian healthcare system. Materials and methods. The method of analytical modeling by Markov was used. Modeling was carried out on the basis of the results of a randomized, multicenter open clinical trial of phase III HERA. The time horizon of the model is 10 years. As an alternative to trastuzumab the standard adjuvant therapy regimens for breast cancer given in the current Protocol for the care of breast cancer patients were considered. According to the results of modeling by Markov the methods of “cost-effectiveness” and “cost-utility” were used. The efficiency criterion was the life years gained (LYG). The utility criterion was QALY. The cost of direct medical expenses was taken into account. The cost structure was determined by the Protocol. The cost of drugs was determined by the Register of the Ministry of Health of Ukraine as of 08/07/2019. The cost of medical services was determined by price lists. The cost of correcting side effects of chemotherapy was also taken into account. The discount was 3 % annually. The analysis of the sensitivity of the results was conducted to change the price of trastuzumab and the price of drugs of alternative adjuvant therapy regimens. Results. According to the modeling the average life expectancy of patients with HER2 + breast cancer in the trastuzumab group was 7.32 years, in the standard chemotherapy group it was 6.43 years. In the trastuzumab group, patients received 6.72 QALYs, while in the standard chemotherapy group – 5.80. The adjuvant therapy with trastuzumab gave the patients an additional 0.89 LYG and 0.92 QALY. The costs of treatment during the study in the trastuzumab group averaged 627115.5 UAH per one patient, in the group of the standard chemotherapy it was 501939.6 UAH. The incremental ratios ICER (the cost of 1 additional year of life) and ICUR (the cost of 1 additional QALY) were 140,833.8 UAH and 136088.8 UAH, respectively. Conclusions. The targeted drug trastuzumab is a medicine for the adjuvant therapy of the early stage HER2 + breast cancer with the evidence-based effectiveness. The adjuvant therapy regimen for HER2 + breast cancer with trastuzumab compared to the standard adjuvant chemotherapy with HER2 + is expensive, but gives better results. It gives an average of an additional 0.89 years of life and 0.92 QALY. The pharmacoeconomic analysis based on modeling by Markov and “cost-effectiveness” ","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"43 1","pages":"45-51"},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73563621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The study of the effect of the low molecular analog of neuropeptide Y on behavioral reactions in rats","authors":"A. Zagayko, I. Havrylov, D. Lytkin","doi":"10.24959/cphj.19.1509","DOIUrl":"https://doi.org/10.24959/cphj.19.1509","url":null,"abstract":"“elevated plus-maze”. Results. Experiments in rats showed the presence of anxiolytic properties of the compound without the associated sedative effect. In the tests “open field” and “elevated plus-maze”, the activating effect of the compound on the locomo-tor activity and a decrease in vegetative manifestations were observed. Conclusions. The data obtained indicate that the neuropeptide Y modified fragment is able to affect the anxiety level and research activity of rats; it substantiates the feasibility of further studies of this experimental compound.","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88028552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The comparative study of the anti-inflammatory action of “Аrthritan” and the phytocomposition on its basis","authors":"Y. Naboka","doi":"10.24959/cphj.19.1510","DOIUrl":"https://doi.org/10.24959/cphj.19.1510","url":null,"abstract":"","PeriodicalId":10498,"journal":{"name":"Clinical pharmacy","volume":"73 1","pages":"24-29"},"PeriodicalIF":0.0,"publicationDate":"2019-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74138987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}